Citations

Showing 10 of 108094 citations.

Association of Serum Phosphate Derangement With Mortality in Patients on Continuous Renal Replacement Therapy
Thongprayoon, Charat , Cheungpasitporn, Wisit , Radhakrishnan, Yeshwanter , Cheungpasitporn, Wisit , Thongprayoon, Charat , Petnak, Tananchai , Qureshi, Fawad , Mao, Michael A. , Kashani, Kianoush

Mayo Clinic

Canadian Journal of Kidney Health and Disease | July 26, 2022 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/20543581221114697 | PMID 35923184 Get It

Background: There is limited evidence on the association of serum phosphate with mortality in patients receiving continuous renal replacement therapy (CRRT). Objective: To assess the association of serum phosphate with mortality in critically ill patients requiring CRRT for acute kidney injury (AKI). Design: A cohort study. Setting: A tertiary referral hospital in the United States. Patients: Acute kidney injury patients receiving CRRT from 2006 through 2015 in intensive care units. Measurements: (1) Serum phosphate before CRRT and (2) mean serum phosphate during CRRT were categorized into 3 groups; ≤2.4 (hypophosphatemia), 2.5 to 4.5 (normal serum phosphate group), and ≥4.6 (hyperphosphatemia) mg/dL. Methods: Multivariable logistic regression was used to assess the association between serum phosphate and 90-day mortality. Results: A total of 1108 patients were included in this study. Of these, 55% died within 90 days after CRRT initiation. Before CRRT, 3%, 30%, and 66% had hypophosphatemia, normophosphatemia, and hyperphosphatemia, respectively. Before CRRT, both hypophosphatemia and hyperphosphatemia were significantly associated with higher 90-day mortality with the adjusted odds ratio (OR) of 2.22 (95% confidence interval [CI]: [1.03, 4.78]) and 1.62 (95% CI: [1.21, 2.18]), respectively. During CRRT, 3%, 85%, and 12% had mean serum phosphate in hypophosphatemia, normophosphatemia, and hyperphosphatemia range. During CRRT, hyperphosphatemia was significantly associated with higher 90-day mortality with adjusted OR of 2.22 (95% CI: [1.45, 3.38]). Limitations: Single center, observational design, lack of information regarding causes of serum phosphate derangement. Conclusion: Most CRRT patients had hyperphosphatemia before CRRT initiation but maintain normal serum phosphate during CRRT. Before CRRT, hypo- and hyperphosphatemia, and during CRRT, hyperphosphatemia predicted higher mortality. Trial registration: Not registered.
Prognosis is worse with elevated cardiac troponin in nonacute coronary syndrome compared with acute coronary syndrome
Horiuchi, Yu , Patel, Mitul , Mueller, Christian, Neath, Sean‐Xavier , Christenson, Robert H. , Morgenthaler, Nils G., McCord, James , Nowak, Richard M. , Vilke, Gary M. , Daniels, Lori B. , Apple, Fred S. , Cannon, Chad , Nagurney, John T., Schreiber, Donald , Diercks, Deborah B. , Headden, Gary , Limkakeng, Alexander T. , Wu, Alan H.B. , Ebmeyer, Stefan , Jaffe, Allan S. , Maisel, Alan S. , Daniels, Lori B , Wettersten, Nicholas , Hollander, Judd E. , deFilippi, Christopher R. , Hogan, Christopher , Anand, Inder S. , Jaffe, Allan S. , Peacock, William Frank

Mayo Clinic

Coronary Artery Disease | July 26, 2022 | Volume: 33 | Issue: 5 | Pages: 376-384

10.1097/mca.0000000000001135 | PMID 35880560 Get It

Background Cardiac troponin (cTn) can be elevated in many patients presenting to the emergency department (ED) with chest pain but without a diagnosis of acute coronary syndrome (ACS). We compared the prognostic significance of cTn in these different populations. Methods We retrospectively analyzed the CHOPIN study, which enrolled patients who presented to the ED with chest pain. Patients were grouped as ACS, non-ACS cardiovascular disease, noncardiac chest pain and chest pain not otherwise specified (NOS). We examined the prognostic ability of cTnI for the clinical endpoints of mortality and major adverse cardiovascular event (MACE; a composite of acute myocardial infarction, unstable angina, revascularization, reinfarction, and congestive heart failure and stroke) at 180-day follow-up. Results Among 1982 patients analyzed, 14% had ACS, 21% had non-ACS cardiovascular disease, 31% had a noncardiac diagnosis and 34% had chest pain NOS. cTnI elevation above the 99th percentile was observed in 52, 18, 6 and 7% in these groups, respectively. cTnI elevation was associated with mortality and MACE, and their relationships were more prominent in noncardiac diagnosis and chest pain NOS than in ACS and non-ACS cardiovascular diagnoses for mortality, and in non-ACS patients than in ACS patients for MACE (hazard ratio for doubling of cTnI 1.85, 2.05, 8.26 and 4.14, respectively; P for interaction 0.011 for mortality; 1.04, 1.23, 1.54 and 1.42, respectively; P for interaction <0.001 for MACE). Conclusion In patients presenting to the ED with chest pain, cTnI elevation was associated with a worse prognosis in non-ACS patients than in ACS patients.
Low-toxin Clostridioides difficile RT027 strains exhibit robust virulence
Anwar, Farhan , Roxas, Bryan Angelo P., Shehab, Kareem W. , Ampel, Neil M. , Viswanathan, V. K. , Vedantam, Gayatri , Roxas, Bryan P.

Mayo Clinic

Emerging Microbes & Infections | July 26, 2022 | Volume: 11 | Issue: 1 | Pages: 1982-1993

10.1080/22221751.2022.2105260 | PMID 35880487 Get It

Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets
Borlaug, Barry A. , Jensen, Michael D. , Kitzman, Dalane W. , Obokata, Masaru , Obokata, Masaru , Borlaug, Barry A , Lam, Carolyn S.P. , Rider, Oliver J.

Mayo Clinic

Cardiovascular Research | July 26, 2022 | Volume: 118 | Issue: 18 | Pages: 3434-3450

10.1093/cvr/cvac120 | PMID 35880317 Get It

Abstract Obesity and heart failure with preserved ejection fraction (HFpEF) represent two intermingling epidemics driving perhaps the greatest unmet health problem in cardiovascular medicine in the 21st century. Many patients with HFpEF are either overweight or obese, and recent data have shown that increased body fat and its attendant metabolic sequelae have widespread, protean effects systemically and on the cardiovascular system leading to symptomatic HFpEF. The paucity of effective therapies in HFpEF underscores the importance of understanding the distinct pathophysiological mechanisms of obese HFpEF to develop novel therapies. In this review, we summarize the current understanding of the cardiovascular and non-cardiovascular features of the obese phenotype of HFpEF, how increased adiposity might pathophysiologically contribute to the phenotype, and how these processes might be targeted therapeutically.
Long coronavirus disease-related persistent poor sleep quality and progression of enlarged perivascular spaces. A longitudinal study
Brutto, Óscar H. Del , Mera, Robertino M. , Costa, Aldo F. , Castillo, Pablo R. , Del Brutto, Oscar H , Castillo, Pablo R , Rumbea, Denisse A. , Recalde, Bettsy Y.

Mayo Clinic

Sleep | July 25, 2022 | Volume: 45 | Issue: 9 | Pages: No page available

10.1093/sleep/zsac168 | PMID 35878737 Get It

A Diagnostic Gene Expression Signature for Bladder Cancer Can Stratify Cases into Prescribed Molecular Subtypes and Predict Outcome
Chen, Runpu , Pagano, Ian , Murakami, Kaoru , Goodison, Steve , Vairavan, Ramanathan, Tahsin, Malak , Rosser, Charles J. , Furuya, Hideki , Tahsin, Malak , Rosser, Charles J , Furuya, Hideki , Sun, Yijun , Black, Peter C.

Mayo Clinic

Diagnostics | July 25, 2022 | Volume: 12 | Issue: 8 | Pages: 1801

10.3390/diagnostics12081801 | PMID 35892512 Get It

Bladder cancer is a biologically heterogeneous disease with variable clinical presentations, outcomes and responses to therapy. Thus, the clinical utility of single biomarkers for the detection and prediction of biological behavior of bladder cancer is limited. We have previously identified and validated a bladder cancer diagnostic signature composed of 10 biomarkers, which has been incorporated into a multiplex immunoassay bladder cancer test, Oncuria™. In this study, we evaluate whether these 10 biomarkers can assist in the prediction of bladder cancer clinical outcomes. Tumor gene expression and patient survival data from bladder cancer cases from The Cancer Genome Atlas (TCGA) were analyzed. Alignment between the mRNA expression of 10 biomarkers and the TCGA 2017 subtype classification was assessed. Kaplan–Meier analysis of multiple gene expression datasets indicated that high expression of the combined 10 biomarkers correlated with a significant reduction in overall survival. The analysis of three independent, publicly available gene expression datasets confirmed that multiplex prognostic models outperformed single biomarkers. In total, 8 of the 10 biomarkers from the Oncuria™ test were significantly associated with either luminal or basal molecular subtypes, and thus, the test has the potential to assist in the prediction of clinical outcome.
Associations of Atrial Fibrillation After Noncardiac Surgery With Stroke, Subsequent Arrhythmia, and Death
Siontis, Konstantinos C. , Weston, Susan A., Jiang, Ruoxiang , Roger, Véronique L. , Chamberlain, Alanna M. , Jiang, Ruoxiang , Chamberlain, Alanna M , Gersh, Bernard J. , Noseworthy, Peter A.

Mayo Clinic

Annals of Internal Medicine | July 25, 2022 | Volume: 175 | Issue: 8 | Pages: 1065-1072

10.7326/m22-0434 | PMID 35878404 Get It

Investigation of beam delivery time for synchrotron-based proton pencil beam scanning system with novel scanning mode
Liang, Xiaoying , Liu, Chunbo , Shen, Jiajian , Bues, Martin , Dougherty, Jingjing M. , Parisi, Alessio , Shrestha, Deepak K. , Yaddanpudi, Sridhar, Beltran, Chris , Yaddanapudi, Sridhar , Furutani, Keith M. , Shen, Jiajian , Bues, Martin , Dougherty, Jingjing M , Parisi, Alessio , Beltran, Chris J , Liang, Xiaoying , Yaddanapudi, Sridhar , Li, Heng

Mayo Clinic

Physics in Medicine & Biology | July 25, 2022 | Volume: 67 | Issue: 17 | Pages: 175001

10.1088/1361-6560/ac8410 | PMID 35878611 Get It

Abstract Objective. To investigate synchrotron-based proton pencil beam scanning (PBS) beam delivery time (BDT) using novel continuous scanning mode. Approach. A BDT calculation model was developed for the Hitachi particle therapy system. The model was validated against the measured BDT of 36 representative clinical proton PBS plans with discrete spot scanning (DSS) in the current Hitachi proton therapy system. BDTs were calculated with the next generation using Mayo Clinic Florida system operating parameters for conventional DSS, and novel dose driven continuous scanning (DDCS). BDTs of DDCS with and without Break Spots were investigated. Main results. For DDCS without Break Spots, the use of Stop Ratio to control the transit dose largely reduced the beam intensity and consequently, severely prolonged the BDT. DDCS with Break Spots was able to maintain a sufficiently high beam intensity while controlling transit dose. In DDCS with Break Spots, tradeoffs were made between beam intensity and number of Break Spots. Therefore, BDT decreased with increased beam intensity but reached a plateau for beam intensity larger than 10 MU s −1 . Averaging over all clinical plans, BDT was reduced by 10% for DDCS with Break Spots compared to DSS. Significance. DDCS with Break Spots reduced BDT. DDCS has the potential to further reduce BDT under the ideal scenario which requests both stable beam intensity extraction and accurately modelling the transit dose. Further investigation is warranted.
A Decision-Support System to Schedule Rotations for Trainees
Shahraki, Narges, Sır, Mustafa Y. , Prindle, Traci, Ramar, Kannan

Mayo Clinic

ATS Scholar | July 25, 2022 | Volume: 3 | Issue: 3 | Pages: 425-432

10.34197/ats-scholar.2021-0109oc | PMID 36312799 Get It

Abstract Background Each training program has its own internal policies and restrictions, which must be considered while developing trainee schedules. Designing these schedules is complex and time consuming, and the final schedules often contain undesirable aspects for trainees. Objective We developed a decision-support system (DSS) to optimally schedule daily assignments and monthly rotations for trainees. The proposed DSS aims to 1) reduce the schedule development time, 2) maximize trainee preferences for desired rotations and vacation times, and 3) ensure adaptability of the DSS across multiple graduate medical programs through a flexible design and intuitive graphical user interface. Methods Using mixed-integer linear programming, we developed a scheduling model that 1) maximized trainees’ preferences on specific rotations and vacation times and 2) ensured fairness by assigning equal numbers of vacation days and a balanced schedule of difficult versus easy rotations among trainees. The model was successfully implemented in the Mayo Clinic Division of Pulmonary and Critical Care for the academic year 2018–2019. Results Using the DSS, it took only a few minutes to produce a schedule versus several days of preparation time required by the manual process. Compared with the manually developed schedule, the DSS schedule satisfied 11% more rotation preferences and improved fairness by 19%. All trainees met duty hours in the DSS schedule compared with 83% in the manually developed schedule. Conclusion The proposed DSS can dramatically reduce the schedule preparation time, accommodate more of trainees’ preferences, and improve fairness in assigning rotations.
Management of Atrial Fibrillation Across the Spectrum of Heart Failure With Preserved and Reduced Ejection Fraction
Reddy, Yogesh N.V. , Borlaug, Barry A. , Gersh, Bernard J. , Nishimura, Rick , Borlaug, Barry A , Gersh, Bernard J

Mayo Clinic

Circulation | July 25, 2022 | Volume: 146 | Issue: 4 | Pages: 339-357

10.1161/circulationaha.122.057444 | PMID 35877831 Get It

Atrial fibrillation (AF) is the most common arrhythmia among patients with heart failure (HF), and HF is the most common cause of death for patients presenting with clinical AF. AF is frequently associated with pathological atrial myocardial dysfunction and remodeling, a triad that has been called atrial myopathy. AF can be the cause or consequence of clinical HF, and the directionality varies between individual patients and across the spectrum of HF. Although initial trials suggested no advantage for a systematic rhythm control strategy in HF with reduced ejection fraction, recent data suggest that select patients may benefit from attempts to maintain sinus rhythm with catheter ablation. Preliminary data also show a close relationship among AF, left atrial myopathy, mitral regurgitation, and HF with preserved ejection, with potential clinical benefits to catheter ablation therapy. The modern management of AF in HF also requires consideration of the degree of atrial myopathy and chronicity of AF, in addition to the pathogenesis and phenotype of the underlying left ventricular HF. In this review, we summarize the contemporary management of AF and provide practical guidance and areas in need of future investigation.